@X What makes you think KERX’s future is tied to Akebia’s Vadasdustat vis a vis FGEN?
Auryxia is ready to replace Renvela and prescribe for IDA NOW and DaVita, and now potentially Fresenius, are wide open for business representing 70% of renal provider services combined — and EU coming. Vifor Fresenius has a complete arsenal of products and now potentially Auryxia in the making.— Vadadustat work on progress but meanwhile VF has an arsenal.
KERX/AKBA merger has NOTHING to do with Vadadustat vis a vis FGEN, and everything to with a machination transaction employed allowing for VF to eventually acquire KERX/AKBA at the cheap while shareholders get fleeced, the short operation makes a fortune, big boys and Big Pharma win — little guy is disposable.
Today’s KERX/AKBA’s trading action in perfect concerto, both, long side (accumulation at cheap) and short side (fleecing and pps takedown) was a major heist.
Nothing to do with Vadadustat or FGEN. As far as KERX is concerned — has to do with Auryxia falling in VF’s lap.
Sanofi loses again, just like they did with Relypsa (Veltassa).
ALL above, in my opinion...
